Biophysical and physiological properties of porcine surfactant enriched with polymyxin B.

Abstract

OBJECTIVE:

We examined whether the biophysical and physiological properties of Curosurf were improved by the cyclic amphipathic decapeptide polymyxin B (PxB).

METHODS:

Curosurf was diluted to 1-5 mg/ml with PxB added at 1, 2 or 3% (w/w). Albumin was added at 40 mg/ml. Minimum surface tension (gammamin) during surface compression was determined for each mixture with pulsating bubble. Immature newborn rabbits were treated with 2.5 ml/kg of Curosurf 80 mg/ml, or Curosurf 32 mg/ml with or without 2% PxB and ventilated for up to 5 h.

RESULTS:

At surfactant concentration 2 mg/ml, gammamin was high (17 +/- 8.9 mN/m) but remained low (2.7 +/- 0.8 mN/m) when PxB was added. Albumin inactivated Curosurf at both 2 and 3.5 mg/ml; this inactivation was prevented by 2% PxB. Treatment of newborn rabbits with Curosurf 80 mg/kg + 2% PxB significantly decreased incidence of pneumothorax in comparison with controls but had no significant effect on lung-thorax compliance or alveolar expansion.

CONCLUSION:

Addition of 2% PxB improves surface activity of Curosurf at low concentration, increases its resistance to inactivation by albumin, and reduces the incidence of pneumothorax in immature newborn rabbits undergoing prolonged ventilation.

• Authors: A Calkovska, M Some, B Linderholm, J Johansson, T Curstedt, B Robertson
• Journal: Biology of the neonate (Biol Neonate) Vol. 88 Issue 2 Pg. 101-8 ( 2005) ISSN: 0006-3126 [Print] Switzerland
• PMID: 15860913 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright (c) 2005 S. Karger AG, Basel.

Chemical References

• Albumins
• Biological Products
• Phospholipids
• Pulmonary Surfactants
• Surface-Active Agents
• Polymyxin B
• poractant alfa

Topics

• Administration, Inhalation
• Albumins (metabolism)
• Animals
• Animals, Newborn
• Biological Products (administration & dosage)
• Lung Compliance (drug effects)
• Lung Diseases (drug therapy, etiology, prevention & control)
• Phospholipids (administration & dosage)
• Polymyxin B (administration & dosage)
• Pulmonary Surfactants (administration & dosage)
• Rabbits
• Respiration, Artificial (adverse effects)
• Surface Properties (drug effects)
• Surface-Active Agents (administration & dosage)